Clinical trials: Left Ventricular Dysfunction Post Myocardial Infarction, open to volunteers
AMI, STEMI
DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction
Recent clinical trials have proven the cardiovascular benefits of new medications for patients with heart failure with reduced ejection fraction (HFrEF), especially sodium-glucose co-transporter 2 (SGLT2) inhibitors.
- Conditions
- AMI, STEMI, NSTEMI, Left Ventricular Dysfunction
- Trial name
- DAPAPROTECTOR (NCT05764057)
- Testing
- Dapagliflozin propanediol (FORXIGA™/FARXIGA™1)
- Where
- France
- Volunteers
- 450 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris